Dividend Information and Recent Developments for Agilent Technologies: Key Insights Before the Ex-Dividend Date on Sep 30, 2025

Agilent Technologies Inc. (A) recently announced a cash dividend of $0.2480 per share, marking the third consecutive quarter with the same amount. The ex-dividend date is set for Sep 30, 2025, with the payment to be distributed on Oct 22, 2025. The average of the last 10 dividend payments per share is approximately $0.1639, indicating that this current payout is higher than the historical average. The announcement date for the dividend was Sep 17, 2025, and the last dividend was issued on Jul 23, 2025, also at the rate of $0.2480 per share. Investors should note that Sep 30, 2025, is the final day to purchase the stock and still qualify for the dividend; any transactions after this date will not grant entitlement to the payout.

Over the past week, Agilent Technologies has made significant strides in advancing precision medicine through a strategic partnership with Lunit, a leading AI diagnostic firm. The two companies recently announced a non-exclusive collaboration to co-develop AI-powered companion diagnostic solutions that enhance the accuracy and efficiency of biomarker testing. This initiative combines Agilent’s expertise in tissue-based diagnostics with Lunit’s AI algorithms, aiming to accelerate the development of next-generation diagnostic tools for pharmaceutical research and clinical trials. The partnership is seen as a major step forward in integrating artificial intelligence into oncology, potentially benefiting both drug developers and patients by enabling more precise and timely treatment options.

In addition, Agilent Technologies has demonstrated strong financial performance, with its third-quarter fiscal 2025 earnings reported at $1.37 per share, exceeding analyst expectations by 0.74%. This marks a 3.8% increase compared to the previous period, reflecting the company’s robust operational efficiency and solid demand across its key markets. Investors and analysts have taken note of the firm’s consistent performance, with recent reports highlighting its 10.10% revenue growth, a sign of healthy expansion across its three primary business segments.

Since the last update, Agilent has also announced its participation in the 2025 Bank of America Global Healthcare Conference, signaling its commitment to engaging with the broader investment community. Meanwhile, the company continues to explore collaborative research opportunities, including a newly established Open Biopharma Research Hub with Chungnam National University, which aims to drive innovation in biopharmaceutical development.

In conclusion, Agilent Technologies remains in a strong position both financially and strategically, with recent advancements in AI diagnostics and solid earnings performance reinforcing its market standing. Investors considering participation in the upcoming dividend should be aware that the ex-dividend date is Sep 30, 2025, meaning any purchase of Agilent’s stock after this date will not qualify for the $0.2480 per share payout on Oct 22, 2025.